Publication
Article
Author(s):
Faculty
Gary M. Besinque, PharmD
Pharmacist Evidence Analyst and Strategist
Drug Information Services—California Regions
Kaiser Permanente
Downey, California
Adjunct Assistant Professor of Clinical Pharmacy
University of Southern California School of Pharmacy
Los Angeles, California
Cassandra A. Lickert, MD
Senior Medical Liaison
Medical Managed Markets, Health Economics and Outcomes Research
Actelion Pharmaceuticals US, Inc
South San Francisco, California
Susan Raspa, RN, BSN
Senior Medical Liaison
Medical Managed Markets, Health Economics and Outcomes Research
Actelion Pharmaceuticals US, Inc
South San Francisco, California
George Ruiz, MD, MBA
Director
Pulmonary Hypertension Program
Medstar Heart Institute
Washington, DC
Acknowledgment: Faculty wishes to acknowledge the contributions and editorial support of Janis Pruett, RN, MSN, EdD, CDE, FNP-BC.
Faculty Disclosures
These faculty report relationships with the following organizations:
Cassandra A. Lickert, MD
Employment and stock ownership: Actelion Pharmaceuticals US, Inc
Susan Raspa, RN, BSN
Employment and stock ownership: Actelion Pharmaceuticals US, Inc
George Ruiz, MD, MBA
Speakers bureau: Actelion Pharmaceuticals US, Inc; United Therapeutics
Gary M. Besinque, PharmD, reports no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially fatal cardiopulmonary syndrome that imposes a substantial burden both on patients in terms of morbidity and mortality and on managed care organizations in terms of resource utilization. This supplement to The American Journal of Managed Care presents managed care decision makers with information and evolving clinical evidence in support of the potential for combination therapy to become the standard of care for patients with PAH.